Unlocking New Markets: Valneva’s German Expansion Strategy through CSL Seqirus Partnership
Valneva strengthen its German market presence through signing an exclusive agreement with CSL Seqirus for vaccine marketing and distribution.
- On 26th June 2025, Valneva SE, a leading vaccine manufacturer, has entered into a marketing and distribution agreement with leading influenza vaccine manufacturer, CSL Seqirus. Under this agreement, Valneva’s three vaccines will be distributed by CSL Seqirus in Germany.
Dipal Patel, CCO at Valneva SE, “We are excited to join forces with CSL Seqirus to continue developing our commercial sales in this country. CSL’s strong commercial presence in Germany will ensure seamless distribution of our products in Europe’s largest travel vaccine market.”
This distribution agreement to expand in Germany is a breakthrough for the company’s diversifiation policy, as this is expected to rapidly increase the company’s sales due to the availability of numerous opportunities. The country is known as an innovation hub for immunization, and it is at the center of Europe’s biopharmaceutical innovation, highlighting its emergence as a significant biopharmaceutical distributor.
Bundesrepublik Deutschland’s Immunization System: A Market of Growing Significance
The country’s robust immunization infrastructure, highest healthcare spending in Europe and strong partnerships with GAVI and WHO for immunization drive the demand for vaccines. Furthermore, the growing demand for travel vaccines, due to uneven distribution and vaccine stock-out, signals a big opportunity for other manufacturers to enter the market.
Furthermore, strong demand for immunization in Germany is expected to accelerate the need for Valneva’s products in the coming years. Excellency Federal Minister, Reem Alabali Radovan, stated that “our country will stay committed to protecting people worldwide from diseases. This will further require strong international partnerships.
Valneva’s Strategic Move
The company has analyzed this opportunity and entered this partnership for three years, under which CLS is going to commercialize Valneva’s IXCHIQ for chikungunya and IXIARO for Japanese encephalitis from July 2025, followed by DUKORAL commercialization in January 2026. These vaccines will further pave the way for future launches across travel vaccine industry.
Thomas Lingelbach, CEO, Valneva, said “We are an emerging company in the global market and contributing to expanding travel vaccination sector through our two major products, one for the Japanese encephalitis and another against Cholera are driving major revenues.”
Impact of Partnership on Immunization
Valneva-CSL Seqirus agreement set an example that companies are transforming the immunization industry through localized partnerships. Moreover, this collaboration will help to improve the country’s immunization challenges, such as product shortage, uneven vaccine distribution, and recently lowered vaccination coverage.
